Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Fineline Cube Aug 6, 2026
Company Drug

CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer

Fineline Cube Aug 6, 2026
Company Drug

Salubris Pharma’s Xinchaotuo Gains NMPA Approval for Primary Hypertension

Fineline Cube May 28, 2025

China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that it has received marketing approval...

Company Deals

Jiangsu Nhwa’s Investee Jiangsu Haoxinqing Plans Overseas Listing

Fineline Cube May 28, 2025

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced that its investee company Jiangsu Haoxinqing...

Company Deals

Shenyang Xingqi Pharmaceuticals Plans Private Placement to Fund R&D Center

Fineline Cube May 28, 2025

China-based Shenyang Xingqi Pharmaceutical Co., Ltd (SHE: 300573) announced plans for a private placement of...

Company Drug

Novartis’ Beovu Approved by NMPA for Diabetic Macular Edema Treatment

Fineline Cube May 28, 2025

Swiss giant Novartis’ (NYSE: NVS) Beovu (brolucizumab) received approval from China’s National Medical Products Administration...

Company Drug

Mabworks’ MIL62 Gains NMPA Review for NMOSD Treatment

Fineline Cube May 28, 2025

China-based Beijing Mabworks Biotech Co., Ltd announced that its New Drug Application (NDA) for MIL62,...

Company Deals

EpimAb Biotherapeutics and Juri Biosciences Ink Global Licensing Deal for KLK2-CD3 T-Cell Engager

Fineline Cube May 28, 2025

Shanghai-based biotech EpimAb Biotherapeutics announced a global licensing agreement with US-headquartered Juri Biosciences, Inc., a...

Company Deals Drug

Eli Lilly to Acquire SiteOne Therapeutics for Up to USD 1 Billion

Fineline Cube May 28, 2025

US-based pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced plans to acquire compatriot biotech...

Company Drug

Junshi Biosciences’ Junshida Wins NMPA Approval for HeFH and Statin-Intolerant Patients

Fineline Cube May 28, 2025

China’s Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...

Company Drug

Sino Biopharmaceutical Presents TQB2102 Phase I Results at ASCO 2025

Fineline Cube May 28, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary results from a Phase I clinical study...

Company

BeiGene Rebrands to BeOne Medicines and Relocates to Switzerland

Fineline Cube May 28, 2025

BeiGene (NASDAQ: ONC, HKG: 6160, SHA: 688235), a global oncology company, has officially rebranded to...

Company Deals Drug

Betta Pharmaceuticals Partners with BioRay for Herceptin Biosimilar Anruize

Fineline Cube May 28, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced a strategic partnership with fellow domestic firm BioRay Biopharmaceutical....

Company Medical Device

China’s NMPA Approves Lifetech’s Aortic Fenestration Stent System

Fineline Cube May 28, 2025

China’s National Medical Products Administration (NMPA) recently approved an innovative aortic in-situ fenestration branch reconstruction...

Company Drug

Phanes Therapeutics Doses First Patient in CD73 Antibody Clinical Study

Fineline Cube May 28, 2025

Sino-US biotech Phanes Therapeutics Inc. announced the first patient dosing in a clinical study for...

Company Drug

StarryGene Initiates Phase II Study of XMVA09 for Wet AMD Treatment

Fineline Cube May 27, 2025

Hefei-based gene therapy biotech StarryGene announced the initiation of a Phase II clinical study for...

Company Deals

Sinotau Pharma Files for HK IPO Focused on Radiopharmaceutical Pipeline

Fineline Cube May 27, 2025

China-based Beijing Sinotau International Pharmaceutical Technology Co., Ltd., a leader in nuclear medicine (radiopharmaceuticals), announced...

Company Deals

Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC

Fineline Cube May 27, 2025

Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech...

Company Drug

Eisai’s Dayvigo Granted NMPA Approval for Insomnia Treatment

Fineline Cube May 27, 2025

Japan-based Eisai Co., Ltd. (TYO: 4523) announced that it has received marketing approval from China’s...

Company Deals

Harbin Gloria Partners with Kowa Pharmaceuticals to Promote Parmodia in China

Fineline Cube May 27, 2025

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced last week that it has entered...

Company Drug

BeiGene and Amgen Report Positive Results for Tarlatamab in Chinese ES-SCLC Patients

Fineline Cube May 27, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology company proposing to rename...

Company Deals

Ayshealth Technology Secures Angel Funding for Artificial Blood Vessel Research

Fineline Cube May 27, 2025

Guangzhou-based Ayshealth Technology, a developer of tissue repair and reconstruction devices, has reportedly secured an...

Posts pagination

1 … 192 193 194 … 704

Recent updates

  • Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance
  • Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer
  • Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%
  • CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer
  • Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance

Company Drug

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Company

Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%

Company Drug

CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.